DocGo Inc. reports developments in technology-enabled mobile health, medical transportation, remote patient monitoring and virtual care. The company’s care delivery platform combines in-home or workplace treatment with remote physicians, a 50-state virtual care network and integrated Ambulnz medical transport services.
Recurring news themes include quarterly and annual results, revenue guidance, customer expansions, EMS hiring and efficiency initiatives, investor conference presentations, governance and compliance recognition, and activity at SteadyMD, DocGo’s virtual care division. Company updates also describe demand for clinician-led telehealth programs, including branded GLP-1 weight loss care support.
DocGo (Nasdaq: DCGO) reported Q4 and full-year 2025 results and raised 2026 guidance after customer expansions and efficiency gains. Q4 revenue was $74.9M (Q4 2024: $120.8M) and full-year revenue was $322.2M (2024: $616.6M), driven by wind-down of migrant-related programs. GAAP gross margin was 27.2% in Q4; adjusted EBITDA loss improved to a projected $5–$10M for 2026. The company recorded significant non-cash impairments in 2025 and acquired SteadyMD on October 20, 2025.
DocGo (Nasdaq: DCGO) will release its fourth quarter and full year 2025 financial results after market close on Monday, March 16, 2026. Management will host a conference call and webcast at 5:00 p.m. ET to discuss results and the company outlook for 2026.
Investors can join by phone (U.S. 1-800-717-1738; international 1-646-307-1865) using Conference ID 74028, or listen via the webcast under Events on the company investor website.
DocGo (Nasdaq: DCGO) said CEO Lee Bienstock will attend the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 and present at 9:10 AM ET. A live webcast will be available via the company’s investor relations website.
DocGo (Nasdaq: DCGO) said its virtual care division, SteadyMD, will expand clinical staff by up to 50% over the coming weeks to meet accelerating demand for clinician-led telehealth supporting branded GLP-1 weight loss care.
The hiring targets multi-state licensed clinicians (five or more active state licenses) to support nationwide delivery and onboarding is expected to begin in the next several weeks. The move aims to scale partnerships with consumer, healthcare, and digital wellness customers, including multiple Fortune 10 brands.
DocGo (Nasdaq: DCGO) announced that Chief Financial Officer Norm Rosenberg will participate in a fireside chat at the 28th Annual Needham Growth Conference on Wednesday, January 14, 2026 at 1:30 PM ET.
Rosenberg will also take part in one-on-one investor meetings. A live webcast of the fireside chat will be available on DocGo's investor relations website at https://ir.docgo.com/.
DocGo (Nasdaq: DCGO) said management will participate in three investor conferences in December 2025: Noble Capital Markets Emerging Growth Conference on December 3, Citi 2025 Global Healthcare Conference on December 4, and iAccess Alpha Best Ideas Conference on December 9–10.
CEO Lee Bienstock will deliver presentations at Noble (Dec 3 at 1:00 PM ET) and iAccess (Dec 9 at 1:00 PM ET) and will attend 1x1 meetings at all listed events. Webcasts of the two presentations will be available on DocGo's investor relations site at https://ir.docgo.com/.
DocGo (Nasdaq: DCGO) said management will participate in four investor conferences in November 2025: the 17th Annual Southwest Ideas Conference on November 19, Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on November 20, Needham Sixth Annual Tech Week on November 21, and the BTIG Digital Health Forum on November 24.
CFO Norm Rosenberg will present at the Southwest Ideas Conference on Nov 19 at 2:20 PM ET with a webcast available on DocGo’s investor relations site. CEO Lee Bienstock and CFO Norm Rosenberg are scheduled for 1x1 meetings at the Canaccord and Needham events. CEO Bienstock will join a BTIG panel on Care Gap Closure and Mobile Health Support at 11:00 AM ET on Nov 24.
DocGo (Nasdaq: DCGO) reported third quarter 2025 results with total revenue $70.8M, down from $138.7M a year ago due to the wind-down of migrant-related programs.
Excluding migrant-related revenue, core revenue rose 8% to $62.4M. GAAP gross margin was 20.0% and adjusted gross margin was 33.0%. Net loss was $29.7M, which included $16.7M of non-cash impairments. Adjusted EBITDA loss was $7.2M. Cash and equivalents were $95.2M as of Sept 30, 2025, after repaying a $30M line of credit; operating cash flow was $1.7M for the quarter.
Company reported record volumes across major lines (transportation +2.5%, care gap +320%, phlebotomy +11%, RPM +6%), completed the acquisition of SteadyMD, and provided 2025 and 2026 guidance: 2025 revenue $315–320M (including $68–70M migrant revenue) and adjusted EBITDA loss $25–28M; 2026 revenue $280–300M with adjusted EBITDA loss $15–25M.
DocGo (Nasdaq: DCGO) announced a partnership with a California health plan to launch Longitudinal Care Services targeting 10,000 under‑engaged plan members. The program combines on‑site mobile clinicians and telehealth to deliver preventive care, chronic care management and transitions of care, with clinicians using connected diagnostic equipment supervised by virtual advanced practice providers. The expansion with a current partner is expected to launch in Q4 2025 and aims to address care gaps that drive ER use and worsening chronic conditions.
The company highlighted its 50‑state virtual care platform, mobile health and ambulance services as supporting capabilities and included a forward‑looking disclaimer about risks and uncertainties.
DocGo (Nasdaq: DCGO) will release third quarter 2025 results for the period ended September 30, 2025 after market close on Monday, November 10, 2025.
Management will host a conference call and webcast the same day at 5:00 p.m. ET. Dial-in numbers: 1-800-717-1738 (U.S.) and 1-646-307-1865 (international); Conference ID: 87106. A webcast will be available under Events in the Investors section at https://ir.docgo.com/. The release covers Q3 2025 financial results and a management discussion on performance and outlook.